Asset
PALIFOSFAMIDE
ALAUNOS THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00421135 | phase1 | completed | 2006-02-01 | 2007-10-01 | Alaunos Therapeutics | A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer |
| NCT01703754 | phase2 | terminated | 2013-04-04 | 2014-08-07 | Alaunos Therapeutics | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. |
| NCT00439686 | phase1_2 | completed | 2006-02-21 | 2008-01-16 | Alaunos Therapeutics | Study of ZIO-201 in Advanced Sarcoma |
FDA applications (0)
This company has no applications containing this asset.